RecruitingObesityVascular Health
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
Eligible age
30–60 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The study will assign participants to take either the medication, empagliflozin or a placebo for 12 weeks. The goal of the study is to determine the effects of empagliflozin on arterial health in Veterans with obesity.
Sponsor: VA Office of Research and Development
You may qualify if…
- ✓ Body mass index (BMI) 30-45 kg/m2
- ✓ 30-60 years of age at randomization
- ✓ Evidence of arterial stiffening (defined as Carotid femoral PWV\>age-predicted) at screening visit (PMID: 20530030)
You may not qualify if…
- ✕ Unable to provide consent
- ✕ Diabetes mellitus
- ✕ Uncontrolled hypertension (\>180/90mmHg) or systolic \<100mmHg at screening visit
- ✕ Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease or stroke
- ✕ Diagnosis of chronic kidney disease
- ✕ Active cancer (excluding basal cell carcinoma or stage 1 squamous cell carcinoma of the skin)
- ✕ Excessive alcohol consumption (\>14 drinks/week for men, \>7 drinks/week for women)
- ✕ Use of GLP-1 analogs or SGLT2 inhibitors
Where it's recruiting
Missouri
Columbia
Source: ClinicalTrials.gov · NCT06745063 · last updated 2025-11-14